Richard Mason’s Post

Apollo Therapeutics will be at the Jefferies Global Healthcare Conference in New York City. Our CEO Richard Mason, will be hosting one-on-one meetings on Tuesday, June 4, which can be booked via Jefferies, or alternatively, please do let us know directly if you would like to connect at the conference. We look forward to seeing you there! #JefferiesHealthcare #investor #conference

Our CEO Richard Mason will be presenting an overview of Apollo Therapeutics at the Evercore ISI 2024 Emerging Biotech Conference tomorrow (Thursday, February 29) at 10:45 – 11:15 ET. #biotech #conference

Apollo Therapeutics will be attending the Cowen Inc. 44th Annual Health Care Conference in Boston, US next week from March 4-6. Our CEO Richard Mason and CFO Jamie Heath will be hosting one-on-one meetings on Tuesday, March 5 - meeting slots can be booked via Cowen or please do let us know directly if you would like to connect at the conference.   We look forward to seeing you there!  #biotech #conference

📈 Breaking boundaries in 2023! The UK #Biotech sector stands strong, attracting £1.8 billion in equity investments despite economic headwinds. The UK #biotech financing 2023 report highlights the sector's resilience and long-term investor returns 🚀 Explore the key insights shaping the future of biotech ➡️ https://lnkd.in/e94GgQWd Thank you to our contributors 👇 📌 Daniel Mahony, BIA Board Chair and Life Sciences Investment Envoy 📌 Emily Pilkington, HSBC Innovation Banking 📌 Dr Richard Mason FRCP, Chief Executive Officer, Apollo Therapeutics 📌 Robert Thong, Chief Executive Officer, Multiomic Health 📌 Marion Bernard, Chief Investment Officer, Northern Gritstone via Kate Spencer 📌 Emma Johnson, Senior Investment Manager, British Patient Capital 📌 Dr Allan Marchington, Head of Life Sciences, ICG 📌 Kevin Lee, Chief Executive Officer, Bicycle Therapeutics 📌 Adrian (Ad) Rawcliffe, CEO, Adaptimmune 📌 Julia Hoggett, CEO, London Stock Exchange 📌 Jonny Ohlson, Founder and Executive Chair, Touchlight #UKBiotech #InvestinBiotech

SEARCHING FOR INDEPENDENT MINDS TO HELP US REIMAGINE DRUG DEVELOPMENT Apollo Therapeutics is a portfolio biopharmaceutical company, rapidly advancing a large and robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. We’re a highly ambitious business, identifying and developing pre-clinical and clinical stage programs with strong biological hypotheses and the potential to become meaningful new treatment options. We’ve just secured $226.5m as part of our series C financing and we’re excited about what the future holds. We are progressing programs across multiple therapy areas including oncology and major inflammatory disorders.   We only recruit the very best people who have open minds and who are intensely curious. As we continue to grow rapidly, we’re looking for a Director of Biologics CMC based in Cambridge UK, to join our ambitious team in early 2024.   We are looking for experienced candidates with blue chip pharma, biotech, and/or CDMO experience who will have responsibility for leading multiple programs within our biologics portfolio, ranging from initial drug substance strategies through to late stage scale-up, reporting directly to our VP, Head of CMC.   If we’ve sparked your interest and you want to find out more, then please send an email to [email protected] clearly stating in the email header which role you’re interested in and we’ll send you a recruitment pack.     The closing date for this role is the 1 December 2023.  No agencies please.